The C5 inhibitor ravulizumab was noninferior to eculizumab — the only medication currently approved for a rare blood cell disorder known as paroxysmal nocturnal haemoglobinuria (PNH) — on all coprimary and key secondary efficacy endpoints in what was known as the largest study of patients with PNH, reveals a leading haematologist at the EHA 2018 Congress.
There appear to be significant improvements in patient-reported quality of life (QoL) following tisagenlecleucel infusion in paediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), according a study presented at the recent 23rd Congress of the European Haematology Association (EHA 2018).
Infusion with chimeric antigen receptor T-cell therapy tisagenlecleucel is well tolerated, with no increased toxicities, among patients with acute lymphoblastic leukaemia (ALL) who relapse after first allogeneic stem cell transplant (alloSCT), according to a study presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden. Moreover, patients have achieved minimal residual disease (MRD)-negative and durable remissions.
Adding glasdegib to low-dose cytarabine (LDAC) improves overall survival in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS), even among those who did not reach complete remission (CR), according a poster presented at the recent 23rd Congress of the European Haematology Association (EHA 2018).
Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.
A novel chimeric antigen receptor T-cell construct directed against CD22 was able to rescue children with relapsed or refractory B-cell acute lymphoblastic leukaemia for whom CD19-directed CAR T therapy had failed, offering renewed hope to patients, a study has shown.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.